Why the study?
Non-polio enteroviruses cause conditions including myocarditis in infants, children, and immunocompromised individuals, but there are no approved treatments.
Quercetin-3-glucoside demonstrates preclinical antiviral activity against non-polio enteroviruses, which are known causes of myocarditis and other diseases.
Q3G may merit exploration for enterovirus myocarditis; hypothesis-generating in animal models and should not yet change practice.
Non-polio enteroviruses (NPEVs) are primary causative agents of aseptic meningitis, encephalitis, hand, foot and mouth disease (HFMD), and myocarditis in infants and children and immunocompromised individuals. However, there are no approved treatments for NPEVs. It has been reported that flavonoids are abundantly found in plants and have antiviral activities. In this study, we explored the antiviral potential of quercetin-3-glucoside (Q3G), a natural flavonoid, against NPEVs such as coxsackievirus A16 and B3 (CVA16 and CVB3), enterovirus 71 (EV71), and human rhinovirus 1B (HRV 1B). Q3G showed potent antiviral activity against CVA16, CVB3, EV71, and HRV1B by suppressing the expression of viral RNA at the early stages of infection. Therefore, Q3G inhibits the early stages of the viral replication cycle and may provide an essential alternative for treating EV71, CVB3, CVA16, and HRV1B.
No takes yet. Share an insight, caveat, or question.
Hwa‐Jung Choi (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: